SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Summary

RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, or combination chemotherapy, which uses different ways to stop tumor cells from dividing so they stop growing or die, may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of reducing immunosuppression, and giving interferon alfa and combination chemotherapy, in treating patients who have malignant tumors that develop after organ transplant.

Conditions

• Lymphoma
• Multiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL

bleomycin sulfate

5 mg/m\^2

BIOLOGICAL

recombinant interferon alfa

3.0 x 10\^6 IU/m\^2

DRUG

cyclophosphamide

650 mg/m\^2

DRUG

cytarabine

300 mg/m\^2

DRUG

doxorubicin hydrochloride

25 mg/m\^2

DRUG

etoposide

120 mg/m\^2

DRUG

methotrexate

120 mg/m\^2

DRUG

prednisone

dose varies during initial immunosuppression. During chemotherapy, 60 mg/m\^2.

DRUG

vincristine sulfate

1.4 mg/m\^2

PROCEDURE

conventional surgery

Simple excision, for those patients who have resectable disease after initial immunosuppression.

RADIATION

radiation therapy

For treatment of localized disease that remains after initial immunosuppression.

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Eastern Cooperative Oncology Group

  collaborator NETWORK

• SWOG Cancer Research Network

  lead NETWORK

Principal Investigators

• Lode J. Swinnen, MD · Loyola University

• Leo I. Gordon, MD · Robert H. Lurie Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

15 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1995-05-31

Primary Completion

2003-11-30

Completion

2011-07-31

Countries

• United States

Study Locations